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Abstract
Cisplatin is one of the most widely used and effective anticancer drugs against solid tumors including cerebellar tumor of
the childhood, Medulloblastoma. However, cancer cells often develop resistance to cisplatin, which limits therapeutic
effectiveness of this otherwise effective genotoxic drug. In this study, we demonstrate that human medulloblastoma cell
lines develop acute resistance to cisplatin in the presence of estrogen receptor (ER) antagonist, ICI182,780. This unexpected
finding involves a switch from the G2/M to G1 checkpoint accompanied by decrease in ATM/Chk2 and increase in ATR/Chk1
phosphorylation. We have previously reported that ERb, which is highly expressed in medulloblastomas, translocates insulin
receptor substrate 1 (IRS-1) to the nucleus, and that nuclear IRS-1 binds to Rad51 and attenuates homologous
recombination directed DNA repair (HRR). Here, we demonstrate that in the presence of ICI182,780, cisplatin-treated
medulloblastoma cells show recruitment of Rad51 to the sites of damaged DNA and increase in HRR activity. This enhanced
DNA repair during the S phase preserved also clonogenic potential of medulloblastoma cells treated with cisplatin. In
conclusion, inhibition of ERb considered as a supplemental anticancer therapy, has been found to interfere with cisplatin–
induced cytotoxicity in human medulloblastoma cell lines.
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Introduction
Medulloblastomas are the most common and aggressive
intracranial tumors in children [1,2,3]. They originate from
poorly differentiated neurons of the external granule layer of the
cerebellum and have intrinsic propensity of spreading in CNS via
subarachnoid spaces [4,5,6]. The most common clinical modalities
against medulloblastoma include combination of radiation therapy
(ranging from 20 to 55 Gy) and chemotherapy, which depending
on the severity of the disease may consist of cisplatin or carboplatin
supplemented by lomustine, and/or vincristine [3]. Despite of
relatively good outcome of these therapies and 3-year progression-
free survival rate for those adjuvant chemotherapies reaching
almost 80% [3], recurrent medulloblastomas still represent a
serious medical challenge. Recent detection of estrogen receptor b
(ERb) during development of the cerebellum [7], and its abundant
expression in medulloblastoma clinical samples and in medullo-
blastoma cell lines [8,9] implicates this nuclear receptor in normal
development, however it also suggests its role in malignant
transformation and possibly tumor progression [10,11,12,13,14].
Indeed, it has been recently reported that activation of ERb in
human medulloblastoma cell lines increased cell growth and cell
migration [8], and ER antagonist, ICI182,780, inhibited medul-
loblastoma tumor growth in subcutaneous D283Med nude mouse
model [8]. In addition, we have recently demonstrated that high-
levels of ERb in medulloblastoma are associated with nuclear
translocation of insulin receptor substrate 1 (IRS-1), and the
involvement of nuclear IRS-1 (nIRS-1) in the inhibition of
homologous recombination directed DNA repair (HRR) of double
strand breaks (DSBs). This interference with the DNA repair
process involves a direct interaction between nIRS-1 and the
major enzymatic component of HRR, Rad51 [9]. In this
experimental model, inhibition of ERs by ICI182,780 repressed
IRS-1 nuclear translocation and improved contribution of HRR in
the process of DNA repair of DSBs [9]. Therefore, we conclude
that ERb, in addition to its supporting role in medulloblastoma
cell growth and cell motility, interferes also with DNA repair of
DSBs. This information could be relevant in view of recently
proposed anti-ERb strategy as a supplemental treatment against
Medulloblastomas [8,9]. Our present study demonstrates, howev-
er, that inhibition of ERb by ICI182,780 may be associated with
undesirable side effect. It triggers resistance of human medullo-
blastoma cell lines to cisplatin. This unexpected effect involves a
switch from the G2/M to G1 phase checkpoint accompanied by
the transition from ATM/Chk2 to ATR/Chk1 pathway, and
better cell survival. In addition, we have detected elevated
formation of Rad51 nuclear foci and significantly higher levels
of HRR in the population of cells, which replicate DNA during the
combined treatment of cells with cisplatin and ICI182,780. This
new finding indicates that ICI182,780, by improving HRR, allows
more effective repair of cisplatin-inflicted DNA damage during the
S phase, which may explain decrease in G2/M arrest, improved
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33867cell survival, and partial preservation of the clonogenic growth of
Daoy cells after removal of the genotoxic agent.
Results
Inhibition of ERb correlates with better cell survival in the
presence of cisplatin
Previous studies indicate that the inhibition of ERb may have
anti-tumoral potential against different malignant neoplasms
[12,15,16,17] including Medulloblastomas [8]. To further analyze
this possibility, we have selected human medulloblastoma cell
lines, Daoy, D283Med and D384Med, which express high levels of
ERb in the absence of ERa [9], and asked if the effectiveness of
cisplatin treatment could be enhanced by the ER antagonist,
ICI182,780 [18,19]. Surprisingly, our initial morphological
evaluation, depicted in Fig. 1A, show only limited nuclear damage
(typical for cisplatin treatment; arrowhead), which was accompa-
nied by mitotic figures (asterix), when the cultures of Daoy cells
were exposed to cisplatin (1 mg/ml) in the presence of 10 mM
ICI182,780. Further analyses based on cell membrane permeabil-
ity (ViaCount) and apoptotic DNA damage (TUNEL) confirmed
ICI182,780-mediate protection of Daoy cells from the cisplatin
induced cytotoxicity (Fig. 1B). Quantitatively, an average cell
viability increased from 47.8+/28.4% to 67.9+/25.1% when the
cell were exposed to cisplatin or to cisplatin+ICI182,780,
respectively (45% increase in cell survival). In the same culture
conditions, the percentage of apoptotic cells (TUNEL positive)
decreased from 15.4+/22.1% in the presence of cisplatin to 5.5+/
20.6% in the presence of cisplatin+ICI182,780 (Fig. 1B, lower
panel). In addition, results in Fig. 2A demonstrate that ICI182,780
used at concentrations ranging from 10 nM to 10 mM protected
Daoy cells from cisplatin-induced cell death. In a similar manner,
siRNA against ERb counteracted cisplatin-induced cytotoxicity
(last bar in Fig. 2A), further indicating that ERb is involved in
ICI182,780-mediated cell protection from cisplatin. Another two
human medulloblastoma cell lines, D384Med and D283Med,
tested in the same condition showed 44.3% (significant) and 21.1%
(not significant) increase in cell viability, respectively (Fig. 2B). A
similar trend in cell survival was also observed in two breast cancer
cell lines BT20 and MCF7, which are both known to express ERb
[20]. However, effects of ICI182,780 counteracting cisplatin-
induced cytotoxicity was less pronounced, most likely because
these two breast-cancer cell lines are significantly less sensitive to
the cisplatin treatment (Fig. 2B). Interestingly, we did not observed
any major effects of ICI182,780 on cell survival when tested, in the
absence of cisplatin, in exponentially growing Daoy cells
(10%FBS) at concentrations ranging from 10 nM to 100 mM
(Fig. 2C).
Inhibition of ER affects cisplatin-induced DNA damage
checkpoints
The analysis of cell cycle distribution demonstrated a gradual
shift from G2/M arrest, which usually happens in cisplatin-treated
cells [21], to G1 arrest when the cells treated with cisplatin were
cultured in the presence of ICI182,780 (ICI; Fig. 3A). This
transition in cisplatin-induced cell cycle arrest is already visible at
24 hours (not shown), and became much more apparent at
48 hours time point in which G2/M fraction decreased from
47.1% (cisplatin only) to 30.2% (cisplatin+ICI) and G1 fraction
increased from 24.2% (cisplatin only) to 39.7% (cisplatin+ICI).
Importantly, the continuous cell exposure to cisplatin and
ICI182,780 for 72 hours resulted in two-fold lower level of SubG1
fraction, which represents the population of necrotic and apoptotic
cells (decrease from 13.8% in cisplatin to 5.7% in cisplatin+ICI;
Fig. 3A, lower panel). We have repeated evaluation of cell cycle
distribution in Daoy, D384Med and in D283Med cells several
times and the average data are presented in Fig. 3B. Again, all cell
lines examined show an apparent shift from G2/M to G1 cell cycle
arrest when the cisplatin treatment is accompanied by
ICI182,780-mediated inhibition of ERb.
If indeed this transition in cell cycle distribution is based on
DNA damage/cell cycle checkpoint system, we should observe
also a shift in the phosphorylation pattern between ATM/Chk2
and ATR/Chk1 [22]. Of note, the cisplatin treatment is expected
to trigger G2/M arrest followed by elevated apoptosis [23]. The
results in Fig. 4 demonstrate very low levels of phosphorylation of
ATM, ATR, Chk1 and Chk2 in the absence of DNA damage
(FBS and ICI). Following the treatment with cisplatin (Cis), over 4-
fold increase in ATM/Chk2 phosphorylation and 1.4-fold increase
of ATR/Chk1 phosphorylation were observed after 6 hours. The
phosphorylation pattern between ATM/Chk2 and ATR/Chk1
was reversed when the cisplatin treated cells were compared to the
cells treated with cisplatin + ICI182,780. Quantitatively, ATM/
Chk2 phosphorylations decreased by an average of 2-fold and
ATR/Chk1 phosphorylations increased by an average of 1.5-fold
(Fig. 4B). These results demonstrate that the transition from G2/
M to G1 arrest observed in the presence of ICI182,780 was indeed
accompanied by the transition from ATM/Chk2 to ATR/Chk1
activation.
The cells preconditioned with ICI182,780 show more
effective DNA repair and less DNA damage
Since cellular responses to cisplatin and ICI182,780 are similar
in all cell lines examined, we have selected Daoy cells to explore
molecular basis of ICI182,780–induced resistance to cisplatin. In
addition, effects of cisplatin and ICI182,780 were evaluated in cells
replicating DNA (10%FBS), therefore the cisplatin treatment
which primarily generates DNA-adducts and oxidative DNA
damage [24,25,26] is also expected to cause DNA double strand
breaks (DSBs) [27,28,29]. This happens when the replication forks
are stalled on the cisplatin-induced primary DNA lesions
[29,30,31]. We have used neutral comet assay to evaluate DSBs
formation in Daoy cells treated with cisplatin [32]. The results in
Fig. 5 show the average comet tail moment of 1.6+/20.2 in
control Daoy cells cultured in the presence of 10% FBS (FBS). The
treatment with ICI182,780 (ICI) slightly increased this parameter
to 1.9+/20.5 (not significant). The average tail moment increased
almost 4-fold (from 1.6+/20.2 to 6.3+/22) following cell
exposure to 1 mg/ml of cisplatin (Cis). Importantly, a significant
(*) 2.4-fold decrease in the tail moment (from 6.3+/20.2 to 2.6+/
20.4) was observed when the Daoy cells were treated with
cisplatin in the presence of ICI182,780 (Cis+ICI). This 2.4-fold
decrease in the comet tail moment in the presence of ICI182,780
may suggest that either cisplatin generates less DNA damage, or
that cisplatin-treated cells repair DSBs more effectively following
the inhibition of ERb. To address this question, we have utilized
siRNA strategy against Rad51 – the major DNA repair protein
involved in DSBs DNA repair during S-phase of the cell cycle
[29,33,34]. The comparison between last two bars in Fig. 5
demonstrates that ICI182,780 is not able to rescue Rad51-
deficient Daoy cells from cisplatin; note a significant increase (**)
in comet tail moment from 2.6+/20.4 to 4.5+/20.6 (Fig. 5).
Additionally, results in Fig. 6 show detectable changes in the
phosphorylation pattern of histone H2AX (cH2AX - DNA
damage response protein, which becomes phosphorylated within
mega-basepare regions surrounding DNA strand breaks [28]). The
number of cH2AX nuclear foci is relatively small in untreated
exponentially growing Daoy cells (FBS), which increased dramat-
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33867Figure 1. Inhibition of ERb improves cell survival in the presence of cisplatin. Panel A: Fluorescent images showing nuclear morphology
following labeling of DNA by fluorescent dye 49,6-diamidino-2-phenylindole (DAPI). Exponentially growing monolayer cultures of Daoy cells (10%FBS)
were treated with cisplatin (1 mg/ml) or with cisplatin + ICI182,780 (10 mM) for 48 hours. The images were taken with Nikon Eclipse 400 upright
fluorescent microscope equipped with the motorized Z-axis, EXI-Aqua camera and deconvolution software (SlideBook5). Rectangles indicate
magnified area containing cells in mitosis (asterix); and cells with damaged nuclei (arrowhead). Note that abundant presence of micronuclei (arrow)
and nuclear fragmentation in cisplatin, and much less of the nuclear damage in cells treated by cisplatin+ICI182,780. Original magnification 620.
Panel B: Daoy cell viability evaluated by ViaCount and TUNEL assays. Both assays were adopted for the use with the GUAVA easyCyte 8HT
flowcytometer (Millipore). The Guava/Express Plus and Guava/ViaCount software were used for data analysis and quantification according to the
manufacturer recommendations (Millipore).
doi:10.1371/journal.pone.0033867.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33867ically in the presence of cisplatin (Fig. 6A; compare FBS and Cis).
Despite of an apparent decrease in the DNA damage evaluated by
the neutral comet assay (Fig. 5), the cells treated with cisplatin in
the presence of ICI182780 (Cis+ICI) show an increase in cH2AX
nuclear foci (evaluated by cH2AX/DAPI co-localization), which
may imply more effective recruitment of DNA repair proteins,
including Rad51 [35]. Of note, we have previously reported that
ICI182,780–mediated inhibition of ERb prevented translocation
of IRS-1 to the nucleus and the binding between IRS-1 and
Rad51 after DNA damage [9]. Indeed, results in Fig. 6A (lower
panel) confirmed that only a small fraction of nuclear IRS-1 was
detected in Daoy cells treated together with cisplatin and
ICI182,780, which according to our previous observation is
expected to increase the fraction of Rad51, which in the absence of
nuclear IRS-1 can be recruited more effectively to the sites of
DSBs, supporting HRR [9,36]. The results in Fig. 6B show that
cells in which cisplatin-induced DNA damage was accompanied
by ICI182,780 treatment have significantly greater areas in which
Figure 2. ICI182,780 dose response and tumor cell survival. Panel A: Evaluation of cell viability (ViaCount) of exponentially growing Daoy
cells (FBS) treated with cisplatain (Cis; 1 mg/ml for 48 hrs) in the presence or absence of ERb antagonist, ICI182,780 at indicated concentrations. In one
instance the cells were preincubated for 48 hrs with siRNA against ERb mRNA (siRNA ERb; 200 nM). Inset: Western blot showing effectiveness of ERb
siRNA (200 nM for 48 hrs) tested in exponentially growing Daoy cells. Data represent average values from 3 experiments in triplicate (n=9) with
standard deviation. *indicate values significantly different from Cis (paired student t-test P#0.05). Panel B: Evaluation of cell viability (ViaCount) in
three medulloblastoma (Daoy, D283Med and D384Med) and two breast cancer (MCF7 and BT-20) cell lines. The cells were cultured in 10%FBS (FBS);
10%FBS+ICI182,780 (10 mM) (ICI); 10%FBS+Cisplatin (1 mg/ml) (Cis); and 10%FBS+ICI182,780 (10 mM) + Cisplatin (1 mg/ml) (Cis+ICI) for 48 hrs. Data
represent average values from 2 experiments in triplicate (n=6) with standard deviation. *indicate values significantly different from Cis (paired
student t-test P#0.05). Panel C: Evaluation of cell viability (ViaCount) in exponentially growing Daoy cells (10%FBS) treated with different doses of
ICI182,780 ranging from 10 nM to 100 mM.
doi:10.1371/journal.pone.0033867.g002
ERb Inhibition and Cisplatin Resistance
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33867Figure 3. Effects of ICI182,780 on cell cycle distribution in cisplatin treated Daoy and D384Med cells. Exponentially growing cultures of
Daoy, D384Med and D283 Med cells were treated with cisplatin (0.25 mg/ml) or with cisplatin + ICI182,780 (10 mM) for 24 (not included), 48 and
72 hours. Aliquots of 1610
6 cells/ml were fixed in 70% ethanol; the cells were centrifuged, labeled with propidium iodide/RNaseA solution and
evaluated by Calibur flowcytometer and WinMDI 2.9 software. Panel A: Diagrams of cell cycle distribution (Daoy) from one representative
experiment, which was repeated three times with a similar outcome. Panel B: Average data of cell cycle distribution (G1, S, G2/M) for Daoy,
D384Med and D283Med cells with standard deviation (n=3). Note the presence of a reproducible shift from G2/M to G1 cell cycle arrest between
cisplatin-treated and cisplatin+ICI182,780-treated cells at 48 hrs time point.
doi:10.1371/journal.pone.0033867.g003
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33867Rad51 co-localizes with the sites of DNA labeled by BrdU (de novo
DNA replication). Quantitatively, the number of cells, in which 10
or more Rad51 nuclear foci co-localized with BrdU, increased
almost 40% in the presence of ICI182,780 (Fig. 6B, histogram).
To evaluate if this significantly higher level of Rad51/BrdU co-
localization correlates with increased HRR activity, we used
previously generated in our lab Daoy/DRGFP cells [9], which
stably express the HRR reporter cassette (DRGFP) [37]. Results in
Fig. 7A demonstrate over 20-fold difference in HRR when the
cisplatin treated Daoy/DRGFP cells were compared to Daoy/
DRGFP cultured in the presence of cisplatin+ICI182,780. In
particular, we have detected an average of 21+/24 cells capable
of repairing the DRGFP reporter cassette per 10,000 cells (n=3);
when the cisplatin treatment was accompanied by ICI182,780. In
the absence of ICI182,780, we have detected only 1+/21 cells
capable of reconstituting the DRGFP per 10,000 cells (n=3)
(Fig. 7A; left panel). Note that in the absence of cisplatin (DRGFP
control) the average level of HRR–mediated reconstitution of the
functional GFP is about 3% in exponentially growing Daoy cells
(10%FBS), which increased up to 5% in 10%FBS+ICI182,780
(Fig. 7A right panel, and [9]). Importantly, this ICI182,780-
induced increase in HRR in cells treated with cisplatin correlated
well with increased clonogenic growth of Daoy cells evaluated
after the removal of cisplatin (Fig. 7B). In this experiment, we have
used cisplatin at lower concentration (0.25 mg/ml) and analyzed its
effects in the presence and absence of 10 mM ICI182,780.
Following 24 hours, the cisplatin-containing culture medium was
removed and the cells were re-pleated at 1,000; 3,000; and 10,000
cells/35 mm dish. The clonogenic growth was measured after 2
weeks of the continuous cell growth in the presence of 10%FBS.
The results in Fig. 7B show that 24 hours of cell exposure to
0.25 mg/ml of cisplatin inhibited almost completely their future
clonogenic growth. In contrast, Daoy cells treated with cisplatin in
the presence of ICI182,780 formed an average of 10+/23, 22+/
Figure 4. Inhibition of ERb modulates cisplatin-induced phosphorylation of cell cycle checkpoint proteins. Panel A: Western blot
analyses showing levels of the phosphorylated ATM, ATR, Chk1 and Chk2 in constitutively growing Daoy cells (10%FBS) treated with cisplatin (1 mg/
ml) in the presence (Cis+ICI) or absence (Cis) of ICI182,780 (10 mM). The cells without treatment (FBS), or cells treated with ICI182,780 only (ICI) were
used as controls. Panel B: Densitometry of Western blots depicted in Panel A evaluated by EZQuant-Gel 2.17 software. Levels of pATM, pATR, pChk1
and pChk2, were normalized with the corresponding levels of Grb-2. Data represent averages obtained from densitometric measurements of 3 blots
with standard deviation and each band was normalized with corresponding loading control, Grb-2.
doi:10.1371/journal.pone.0033867.g004
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e3386725 and 72+/28 clones when plated at 1,000; 3,000; and 10,000
cells, respectively. Interestingly, in the absence of cisplatin,
clonogenic growth of Daoy cells was significantly attenuated in
cultures exposed to 10 mM ICI182,780 (Fig. 7C).
Discussion
Results of this study demonstrate that human medulloblastoma
cell lines develop resistance to cisplatin in the presence of a
potential anticancer drug, estrogen receptor (ER) antagonist,
ICI182,780. This unexpected finding involves a switch from
cisplatin-induced G2/M arrest to G1 arrest accompanied by the
activation ATR/Chk1 and inhibition of ATM/Chk2 - DNA-
damage/cell cycle arrest pathway. In addition, cells exposed to
cisplatin and ICI182,780 show elevated recruitment of Rad51 to
the sites of damaged DNA and improved DNA repair by
homologous recombination (HRR). This improved S phase
DNA repair is considered to be responsible for a switch in
cisplatin-induced cell cycle arrest from G2/M to G1 checkpoint,
which correlates with better cell survival and partially preserved
clonogenic growth. Our interpretation of the acquired resistance
to cisplatin is based on the inhibition of ERb-mediated
translocation of IRS-1 to the nucleus [9]. In the absence of
nuclear IRS-1 the recruitment of Rad51 to the sites of damaged
DNA is not disturbed, therefore, Rad51 can support more
effectively DNA repair by homologous recombination [36,38].
This enhanced S phase DNA repair can explain also much lower
fraction of cells arrested in G2/M, and transition in cell cycle
distribution from G2/M to G1 arrest, when the cisplatin treatment
is accompanied by ICI182,780 (Fig. 3). However, a different
interpretation could be also possible. Recent work by Pedram et al.
indicates that ERs agonist, 17-b-estradiol (E2), inhibited ATR/
Chk1 in MCF7 breast cancer cells [39]. In addition, E2-treated
MCF7 cells were characterized by delayed resolution of cH2AX
phosphorylation, decreased Rad51 nuclear foci formation and less
effective DNA repair [39]. Therefore, one could speculate that in
contrast to ER activation, ER inhibition should improve the
contribution of Rad51 to DNA repair. Indeed, this is what we
have observed in medulloblastoma cells treated with both
ICI182,780 and cisplatin (Fig. 6). Moreover, our data show that
the inhibition of ERb leads to enhanced ATR/Chk1 phosphor-
ylation and the expected transition from G2/M to G1 cell cycle
arrest [22], which was associated with better survival of
medulloblastoma cells in the presence of cisplatin (Figs. 1 and 2).
In MCF7 cells, E2-mediated stimulation of ERa and ERb was
accompanied by a decrease in ATR/Chk1 function towards G2/
M arrest, which coincided with less effective DNA repair and
increased chromosomal damage [39]. Again, the major difference
here is that MCF7 cells express high levels of ERa and detectable
levels of ERb [9,40], on the other hand, medulloblastoma cells are
characterized by high levels of ERb and practically undetectable
ERa [9]. Therefore, DNA damage in MCF7 cells in which ERa
and ERb were activated lead to the inhibition of G2/M
checkpoint, which resulted in less effective DNA repair. In our
case however, DNA damage in medulloblastoma cells in which
ERb was inhibited, resulted in transition from G2/M to G1
checkpoint, better DNA repair, and improved cell survival, which
attenuated cytotoxic action of cisplatin.
In view of these results and in respect to anticancer treatment,
ICI182,780, has been already proposed for hormone sensitive
breast cancer especially when the tumor cells develop resistance to
tamoxifen, or to avoid tamoxifen-mediated partial agonistic side
effects in estrogen-sensitive tissues such as endometrium and
uterus [41]. It has been shown also that in difference to tamoxifen,
ICI182,780 binds and inactivates ERa and ERb without any
agonistic effects on these nuclear receptors [18,42]. Although the
role of ERa in several tumors, including breast, ovarian, prostate
and colon cancer has been intensively studied, a potential function
Figure 5. Inhibition of ERb decreases cisplatin-induced DNA damage. Neutral comet assay (single cell electrophoresis) of exponentially
growing Daoy cells (FBS) in which cisplatin treatment (1 mg/ml for 6 hours) was applied in the absence (Cis) or in the presence of 10 mM ICI182,780
(Cis+ICI). The histogram represents average Olive tail moment (with standard deviation) calculated from three experiments in duplicate (n=6). In
each experiment at least 100 cells were selected for the calculation (Automated Comet Assay; Loats Associates. Inc.). * indicates value statistically
different from the sample labeled Cis. ** indicates value statistically different form Cis+ICI (paired student t-test; P#0.05). Inset: Western blot
showing effectiveness of Rad51 siRNA (100 nM for 48 hrs) tested in exponentially growing Daoy cells.
doi:10.1371/journal.pone.0033867.g005
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33867Figure 6. Inhibition of ERb activates recruitment of Rad51 during S phase DNA repair. Panel A: Fluorescent images of Daoy cells
immunolabeled with anti-histone cH2AX (upper panel) and anti-IRS-1 (lower panel) antibodies. The nuclei are visualized by DAPI staining (blue
fluorescence). The histograms represent quantification of the co-localization between cH2AX and DAPI; IRS-1 and DAPI. The data represent average
percentage of nuclear voxels (3-D pixels) of cH2AX (red fluorescence) and IRS-1 (green fluorescence) calculated from three independent experiments
(n=3) in which ten randomly selected cells have been evaluated by the Mask analysis included in SlideBook 5 deconvolution software. * indicates
value statistically different from the sample labeled Cis (paired student t-test; P#0.05). Panel B: Fluorescent images of the cells labeled with anti-
Rad51 (green fluorescence) and with anti-BrdU (red fluorescence) antibodies. Exponentially growing cultures of Daoy cells (10%FBS) were exposed for
one hour to bromodeoxyuridine (BrdU) during the 6 hours treatment with cisplatin (1 mg/ml) in the absence (Cis) or in the presence of 10 mM
ICI182,780 (Cis+ICI). The histogram represents quantification of Rad51 positive cells in which Rad51 nuclear foci co-localize with BrdU-labeled DNA.
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33867of ERb in malignant transformation is still unclear. ERb has been
detected in breast, ovarian, prostate and colon cancer, and in
CNS tumors including glioblastoma and medulloblastoma
[15,16,43,44]. In some of these cancers, ERb levels decline in
close correlation with the development of less differentiated
phenotype [43,45,46], which correlates well with our previous
finding of nuclear ERb in well-differentiated desmoplastic and
neuroblastic medulloblastoma [9]. Additionally, there is an
increasing tendency of using ICI182,780 in combination with
other hormonal, cytotoxic, or genotoxic therapies. For instance,
combine treatment with ICI182,780 and cisplatin demonstrated a
strong synergistic action against ovarian [18] and cervical [19]
cancer cells in vitro. Interestingly, several reports indicate that
anticancer activities of ICI182,780 have been observed also in
cancer cells which are ERa negative [17,18,47,48]. This may
imply the involvement of cellular reactions to the inhibition of
ERb, which are not fully understood and are suspected to be very
different from those, which are related to the inhibition of ERa.I n
this respect, inhibition ERb could have an important impact on
medulloblastoma in which ERb protein levels are high, and levels
of ERa are either very low or practically undetectable [8,9]. For
instance, recently published results by Belcher et al. [8]
demonstrate that activation of ERb in human medulloblastoma
cell line, D283Med, resulted in both increased cell growth and cell
migration, and that ICI182,780 attenuated medulloblastoma
tumor growth in the mouse model based on subcutaneous
injection of D283Med cells. Our present work indicates, however,
that 10 mM ICI182,780 had only a modest inhibitory action on
D384Med medulloblastoma cells, and partially attenuated clono-
genic growth of Daoy cells (Fig. 7B). This particular concentration
of ICI182,780 was selected because it inhibited ERb transcrip-
tional activity in three previously tested medulloblastoma cell lines
[9], and was used in several studies involving prostate cancer cell
lines [11]. We are not certain why in our experimental setting
Daoy and D384Med are much less sensitive to ICI182,780
treatment since they express ERb at the levels comparable to
D283Med, and are all practically negative for ERa [8,9]. The only
obvious difference is the concentration of ICI182,780, which in
our studies is 100-times higher than in the experiments presented
by Belcher et al. [8,9]. Nerveless, Daoy, D384Med and to the
lesser extent D283Med acquire resistance to cisplatin when this
genotoxic agent is used together with 10 mM ICI182,780 (Fig. 2B).
This unexpected side effect observed in cell lines should be
carefully examined in view of the increasing number of preclinical
studies in which combine treatment of cisplatin and ICI182,780
are proposed.
For instance, different cellular responses have been observed in
ovarian [18] and cervical cancer cells [19] in which ICI182,780
improved genotoxic action of cisplatin. These apparent discrep-
ancy in cellular responses to cisplatin + ICI182,780 treatment may
suggest that different cellular context have to be considered during
the selection of ICI182,780 as a supplemental drug for a particular
anticancer therapy. Since ICI182,780 inhibits both ERa and ERb,
and these two nuclear receptors mediate different and often
opposite cellular responses, better understanding of ERb and its
role in normal and pathologic growth of neural progenitors is
absolutely required before pharmacological manipulations target-
ing this nuclear receptor could be used as a clinical regimen
against medulloblastoma. Our present findings suggest for instance
that the combined cisplatin and ICI182,780 treatment may
predispose medulloblastoma cells to recurrences after the geno-
toxic treatment is completed.
Materials and Methods
Cell culture
We have used three human medulloblastoma cell lines, Daoy,
D384Med and D283Med. Daoy derive from a tumor in the
posterior fossa of a 4 years-old boy (ATCC# HTB186), D283Med
(ATCC#HTB-185), and D384Med [49] are metastatic medullo-
blastomas isolated from peritoneal ascites of children diagnosed
with medulloblastoma. Daoy were maintained as monolayer
cultures in Dulbecco’s Modified Eagle Medium (DMEM)
(GIBCO-BRL, Grand Island, NY) containing 10% fetal bovine
serum (FBS), at 37uC in a 7% CO2 atmosphere. D283Med and
D384Med were cultured in suspension in DMEM supplemented
with non-essential amino acids (GIBCO-BRL, Grand Island, NY),
2 mM L-glutamine, 1 mM sodium pyruvate, and 10% FBS. We
have used MCF7 (ATCC# HTB-22) and BT-20 (ATCC# HTB-
19) human breast cancer cell lines as a reference point in the
experiment depicted in Fig. 2B. Exponentially growing cells were
treated with cisplatain at 0.25 and 1.0 mg/ml in the presence or
absence of ERb antagonist, ICI182,780 (10 nM-100 mM; Tocris
Bioscience, Ellisville, Mo) [9]. In some experiments, expression of
Rad51 and ERb was inhibited by utilizing ON-TARGETplus
SMARTpool siRNA against human Rad51 - target sequences:
CCAACGAUGUAAGAAUU; GCAGUGAUGUCCUGGAU-
AA; CUAAUCAGGUGGUAGCUCA; UAUCAUCGCCCAU-
GCAUCA (100 nM, Thermo Scientific); and human ERb - target
sequences: GGAAAUGCGUAGAAGGAAU; UUCAAUUUC-
GAGAGUUA; GCACGGCUCCAUAUACAUA; GAACCCA-
CAGUCUCAGUGA (200 nM; Thermo Scientific) delivered to
the cells by Oligofectamine transfection reagent (Invitrogen).
Cell cycle distribution, DNA replication and Cell viability
We have used GUAVA easyCyte 8HT and Calibur flow
cytometers to detect and quantify these three cellular parameters.
Briefly, the aliquots of 1610
6 cells/ml were fixed in 70% ethanol
at 220uC, overnight. The cells were centrifuged at 1,600 rpm and
the resulting pellets suspended in 1 ml of freshly prepared
Propidium Iodide/RNaseA solution. Cell cycle distribution was
evaluated using specialized software CellCycle included in
GuavaSoft 1.1. In some experiments DNA replication was
evaluated by BrdU pulse labeling (1 hour) using the DNA
replication Assay (Millipore). Finally, cell death and cell survival
were evaluated by two independent assay, TUNEL assay (Roche),
which detects DNA damage associated with apoptosis, and cell
membrane integrity by using ViaCount reagents, according to the
manufacturer recommendations. Guava/Express plus and Gua-
va/ViaCount software were used for data analyses.
Neutral Comet Assay (single cell electrophoresis)
Was utilized to detect DNA strand breaks in exponentially
growing Daoy cells exposed to cisplatin in the presence and absence
of ICI182,780. The cells treated with H2O2 (oxidative DNA
damage) or neocarzinostatin (NCS; Sigma, Saint Louis, MO) were
used as positive controls for the detection of secondary and primary
DNA strand breaks (DSBs), respectively. The cells were subjected to
Note, almost 40% increase in the number of cells utilizing Rad51 to repair cisplatin-induced DNA damage (during DNA replication) when the cisplatin
treatment is accompanied by ICI182,780. * indicates value statistically different from the sample labeled Cis (paired student t-test; P#0.05).
doi:10.1371/journal.pone.0033867.g006
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SYBR green based kit from Trevigen and Automated Comet Assay
System from Loats Associates Inc. The tail moment was calculated
from 100 cells collected per single measurement by utilizing
specialized comet software included in the Automated Comet
Assay System (Loats Associates Inc., Westminster, MD).
Figure 7. Inhibition of ERb improves homologous replication directed DNA repair (HRR) and increases clonogenic growth of Daoy
cells treated with cisplatin. Panel A: HRR was evaluated by the assay based on the reconstruction of the wild type green fluorescent protein
(GFP) from two non-functional heteroallelic fragments of GFP cDNA delivered into cells by the pDRGFP expression vector [37]. HRR was evaluated in
Daoy/DRGFP cells following transient transfection with the expression vector coding for I-Sce-I (rare cutting endonuclease), to inflict DNA double
strand break in GFP cDNA, and with mito-red containing expression vector (control for the efficiency of transfection). The results were collected from
three separate experiments in duplicate (n=6) in which about 10,000 transfected cells per experiment were counted in at least ten randomly selected
microscopic fields. * indicates value statistically different from the sample labeled Cis (paired student t-test; P#0.05). The histogram labeled ‘‘DRGFP
control’’ illustrates baseline HRR in exponentially growing Daoy cells in 10%FBS and in 10%FBS+10 mM ICI182,780. Panel B: Clonogenic assay. The
monolayer cultures of Daoy cells were exposed to cisplatin (0.25 mg/ml) in the presence and in the absence of 10 mM ICI182,780 for 24 hours. Next,
the medium containing cisplatin was replaced with the fresh medium and the cells were plated at the clonal-density (ranging from 1610
3 to 1610
4
cells per 35 mm dish) in the presence of 10%FBS. Clonogenic growth was evaluated after 14 days of a continuous cell growth as described in our
previous work [50]. In control conditions (Panel C), the cisplatin treatment was omitted. The data represent average number of clones with standard
deviation calculated from three independent experiments in duplicate (n=6) *indicates values statistically different (paired student t-test; P#0.05).
doi:10.1371/journal.pone.0033867.g007
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To isolate protein extracts, monolayer cultures were treated
with 400 ml of lysis buffer A [50 mM HEPES; pH 7.5; 150 mM
NaCl; 1.5 mM MgCl2; 1 mM EGTA; 10%glycerol; 1% TritonX-
100; 1 mM phenylmethylsulfonyl fluoride (PMSF); 0.2 mM Na-
orthovanadate and proteinase inhibitor cocktail] on ice for
5 minutes. Total proteins (50 mg) were separated on a 4–15%
gradient SDS-PAGE (BioRad). The resulting blots were probed
with following primary antibodies: anti-pSer1981 ATM mouse
monoclonal antibody (Cell Signaling Technology Inc., Danvers,
MA); anti-pSer428 ATR rabbit polyclonal antibody (Cell
Signaling Inc.); anti-pSer317 Chk1 rabbit polyclonal (Cell
Signaling Inc.), anti-pThr68 Chk2 rabbit polyclonal (Cell
Signaling Inc.). Anti-Grb-2 antibody (Transduction Laboratories,
Lexington, KY), was used to monitor equal loading conditions
[33].
Immunocytofluorescence. All cells were cultured on glass
culture slides (BD Falcon, Franklin Lakes, NJ). Cisplatin
treatment, 0.25–1 mg/ml, was applied to exponentially growing
cells for a period of 6 hours. For immunostaining the cells were
fixed and permeablized with the buffer containing 0.02% Triton
X-100 and 4% formaldehyde in PBS. Fixed cells were washed 36
in PBS and blocked in 5% BSA for 1 hour at 37uC. RAD51 was
detected by rabbit anti-RAD51 polyclonal antibody (Santa Cruz
Inc., Santa Cruz, CA) followed by AlexaFluor-conjugated donkey
anti-rabbit secondary antibody (Invitrogen, Carlsbad, CA).
Phospho-histone H2AX (S139) was detected by a rabbit
polyclonal antibody (UBI, Lake Placid, NY), and rhodamine-
conjugated goat anti-rabbit secondary antibody (Molecular
Probes). IRS-1 was detected by anti-IRS-1 mouse monoclonal
antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA)
followed by FITC-conjugated goat anti-mouse secondary
antibody (Molecular Probes, Inc. Eugene, OR). DNA replication
was monitored by labeling the exponentially growing cells with
Bromodeoxyuridine (BrdU) followed by immunofluorescence with
anti-BrdU antibody, according to manufacturer recommendations
(DNA Replication Assay; Millipore). The images were visualized
with the Nikon Eclipse E400 upright fluorescence microscope
equipped with EXI aqua camera (Qimaging), motorized Z-axis,
and SlideBook5 acquisition/deconvolution software (Intelligent
Imaging Innovations, Inc., Denver, CO). A series of three-
dimensional images of each individual picture were deconvoluted
to one two-dimensional picture and resolved by adjusting the
signal cut-off to near maximal intensity to increase resolution.
Final pictures were prepared with Adobe Photoshop to
demonstrate subcellular localization and co-localization between
detected proteins. Quantification of colocalization between:
Rad51 and DAPI; IRS1 and DAPI; Rad51 and BrdU were
performed by utilizing Mask analysis included in SlideBook5
software according to manufacturer recommendation (Intelligent
Imaging Innovations, Inc).
Clonogenic Growth. Exponentially growing cultures of
Daoy cells (10%FBS) were either untreated (control) or treated
with 0.25 mg/ml of cisplatin for 24 hours. The ICI182,780
pretreatment started 16 hours before cisplatin was applied and
continued for an additional 24 hours in the presence of cisplatin.
Next the cells were washed with fresh serum-free medium,
trypsinized and transferred to 35 mm culture dishes at clonal-
densities ranging from 1610
3 to 1610
4 cells. Clonogenic growth
was evaluated 2 weeks after continuous cell growth in the medium
containing 10%FBS and the resulting clones were fixed and
stained with 0.25% Cristal Violet in methanol as described in our
previous work [50].
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